Search results for "GLUTAMATE"

showing 10 items of 434 documents

Neuronal expression and regulation of rat inhibitor of apoptosis protein-2 by kainic acid in the rat brain

2002

Inhibitors of apoptosis proteins (IAPs) define a protein family with the ability to counteract cell death by the inhibition of different caspases activated during apoptosis. These proteins are present in different cells, however, the function and roles of IAPs in brain tissue are not fully understood. We report here that RIAP-2, the rat homologue of human cIAP-1/HIAP-2, is expressed in different areas of rat brain as shown by in situ hybridization and immunohistochemistry. Brain regions with relatively high expression of RIAP-2 mRNA included cortex, cerebellum and different subregions of rat hippocampus. Double labelling using a specific anti-RIAP antibody and markers for neurons and glial …

Programmed cell deathKainic acidbiologyGeneral NeuroscienceDentate gyrusGlutamate receptorHippocampusIn situ hybridizationInhibitor of apoptosisMolecular biologyCell biologychemistry.chemical_compoundnervous systemchemistrybiology.proteinNeuNEuropean Journal of Neuroscience
researchProduct

Excitotoxin-induced changes in transglutaminase during differentiation of cerebellar granule cells

2002

Excitotoxicity induced by NMDA receptor stimulation is able to increase the activity of many enzymes involved in neuronal cell death. Primary cultures of rat cerebellar granule cells were used to elucidate the role of transglutaminase reaction in the excitotoxic cell response, and to evaluate the role of glutamate receptors in cell survival and degeneration. Granule neurons, maintained in vitro for two weeks, were exposed to NMDA at different stages of differentiation. Following NMDA receptor activation, increases in transglutaminase activity were observed in cell cultures. The levels of enzyme activity were higher in cells at 5 days in vitro than in those at 8-9 or 13-14 days in vitro. Mor…

Programmed cell deathN-MethylaspartateTime FactorsCell SurvivalTissue transglutaminaseNeurotoxinsClinical BiochemistryExcitotoxicityStimulationmedicine.disease_causeReceptors N-Methyl-D-AspartateBiochemistryCerebellummedicineAnimalsRats WistarNeuronsTransglutaminasesbiologyOrganic ChemistryGlutamate receptorCell DifferentiationIn vitroRatsCell biologyAnimals Newbornnervous systemApoptosisNerve Degenerationbiology.proteinNMDA receptorTransglutaminase – Excitotoxicity – Neurodegenerative diseases – Apoptosis – Glutamate – Cerebellar granule neuronsAmino Acids
researchProduct

Integrative proteomics: functional and molecular characterization of a particular glutamate-related neuregulin isoform.

2005

Glutamate is the major excitatory neurotransmitter in the mammalian brain and is related to memory by calcium-conducting receptors. Neuregulins have emerged as long-term modulating molecules of synaptic signaling by glutamate receptors, playing a role in some cognition/memory-related disorders and moreover being part of transient functional microdomains, called lipid rafts. Here we characterize one specific isoform of neuregulin as a central biomarker for glutamate-related signaling, integrating results from in vitro and in vivo models by a differential functional and proteomic approach.

ProteomicsNeuregulin-1Glutamic AcidNerve Tissue ProteinsBiochemistryHippocampusRats Sprague-DawleyAlzheimer DiseaseAnimalsHumansLearningProtein IsoformsNeuregulin 1ReceptorLipid raftCells CulturedbiologyGlutamate receptorGeneral ChemistryGlutamic acidCell biologyRatsbiology.proteinNeuregulinCalciumFemaleSynaptic signalingSignal transductionBiomarkersSignal TransductionJournal of proteome research
researchProduct

In‐depth protein profiling of the postsynaptic density from mouse hippocampus using data‐independent acquisition proteomics

2014

Located at neuronal terminals, the postsynaptic density (PSD) is a highly complex network of cytoskeletal scaffolding and signaling proteins responsible for the transduction and modulation of glutamatergic signaling between neurons. Using ion-mobility enhanced data-independent label-free LC-MS/MS, we established a reference proteome of crude synaptosomes, synaptic junctions, and PSD derived from mouse hippocampus including TOP3-based absolute quantification values for identified proteins. The final dataset across all fractions comprised 49 491 peptides corresponding to 4558 protein groups. Of these, 2102 protein groups were identified in highly purified PSD in at least two biological replic…

ProteomicsPost-Synaptic DensityProteinsHippocampal formationBiologyProteomicsHippocampusBiochemistryCell biologyMiceTransduction (genetics)Glutamatergicnervous systemProteomeAnimalsData-independent acquisitionCytoskeletonMolecular BiologyPostsynaptic densityPROTEOMICS
researchProduct

Antagonists and agonists at the glycine site of the NMDA receptor for therapeutic interventions.

2003

For decades neuroreceptor research has focused on the development of NMDA glycine-site antagonists, after Johnson and Ascher found out in 1987 about the co-agonistic character of this achiral amino acid at the NMDA receptor. Contrary to the inhibitory glycine receptor (glycine(A)) the glycine binding site on the NMDA receptor (glycine(B)) is strychnine-insensitive. A great diversity of diseases showing a disturbed glutamate neurotransmission have been linked to the NMDA receptor. Glycine site antagonists have been investigated for acute diseases like stroke and head trauma as well as chronic ones like dementia and chronic pain.

PsychosisGlycinePainPharmacologyNeurotransmissionInhibitory postsynaptic potentialReceptors N-Methyl-D-AspartateGlycine bindingMemantineDrug DiscoverymedicineAnimalsHumansReceptorGlycine receptorPharmacologychemistry.chemical_classificationBinding SitesEpilepsyOrganic ChemistryGlutamate receptorGeneral Medicinemedicine.diseaseAmino acidStrokeNeuroprotective AgentsBiochemistrychemistryGlycineSchizophreniaNMDA receptorAnticonvulsantsDementiaExcitatory Amino Acid AntagonistsEuropean journal of medicinal chemistry
researchProduct

Phase II study of pemetrexed and cisplatin plus cetuximab followed by pemetrexed and cetuximab maintenance therapy in patients with advanced nonsquam…

2013

Abstract Objectives The aim was to determine if combined pemetrexed, cisplatin, and cetuximab was efficacious and safe as first-line treatment in advanced nonsquamous non-small cell lung cancer (NSCLC). Patients and methods In this single-arm, multicenter clinical trial, patients with Stage IIIB/IV nonsquamous NSCLC received first-line therapy consisting of pemetrexed (500mg/m 2 ) and cisplatin (75mg/m 2 ) on Day 1 (21-day cycles) plus weekly cetuximab (400mg/m 2 loading dose, then 250mg/m 2 ) for 4–6 cycles. Non-progressing patients received maintenance therapy consisting of pemetrexed and cetuximab as above until disease progression. All patients received vitamin supplementation, dexameth…

Pulmonary and Respiratory MedicineOncologyAdultMaleCancer Researchmedicine.medical_specialtyGuanineLung NeoplasmsPhases of clinical researchCetuximabPemetrexedAntibodies Monoclonal HumanizedLoading doseMaintenance ChemotherapyTranslational Research BiomedicalMaintenance therapyGlutamatesInternal medicineCarcinoma Non-Small-Cell LungAntineoplastic Combined Chemotherapy ProtocolsmedicineClinical endpointHumansLung cancerSurvival rateAgedNeoplasm StagingCetuximabbusiness.industryInduction ChemotherapyMiddle Agedmedicine.diseasePemetrexedTreatment OutcomeOncologyFemaleCisplatinbusinessmedicine.drugLung cancer (Amsterdam, Netherlands)
researchProduct

A randomized phase II study of pemetrexed in combination with cisplatin or carboplatin as first-line therapy for patients with locally advanced or me…

2013

Abstract Background Pemetrexed plus cisplatin was approved for first-line treatment of non–small-cell lung cancer (NSCLC) in patients with nonsquamous histology after initiation of this study. This phase II study evaluated pemetrexed plus cisplatin and pemetrexed plus carboplatin as first-line treatments for stage IIIB/IV NSCLC. Patients and Methods The patients were randomized (1:1) to 2 parallel arms: pemetrexed (500 mg/m2) plus cisplatin (75 mg/m2) or pemetrexed (500 mg/m2) plus carboplatin (area under the curve 6) day 1 every 3 weeks (maximum, 6 cycles). Progression-free survival (PFS) was the primary objective; secondary objectives included overall survival (OS), 1-year survival, and s…

Pulmonary and Respiratory MedicineOncologyAdultMaleCancer Researchmedicine.medical_specialtyGuanineLung NeoplasmsPhases of clinical researchKaplan-Meier EstimatePemetrexedNeutropeniaGastroenterologyDisease-Free SurvivalCarboplatinchemistry.chemical_compoundGlutamatesInternal medicineCarcinoma Non-Small-Cell LungAntineoplastic Combined Chemotherapy ProtocolsmedicineHumansNeoplasm MetastasisLung cancerSurvival rateAgedPerformance statusbusiness.industryMiddle Agedmedicine.diseaseCarboplatinPemetrexedOncologychemistryTolerabilityFemaleCisplatinbusinessmedicine.drugClinical lung cancer
researchProduct

Initial topical cooling followed by backtable Celsior flush perfusion provides excellent early graft function in porcine single lung transplantation …

2013

Topical in situ cooling of the donor lungs is a prerequisite for procurement of non-heart-beating donor lungs and may be of interest for living related lung donation.Twenty-four single lung transplants were performed in 4 groups of Landrace pigs (6 per group). Control LPD, control Celsior and topical cooling in situ, followed by LPD (exLPD) or Celsior (exCel) ex situ flush, were employed. All lungs were perfused antegrade with 1 liter of solution at 4°C. Lungs were stored immersed in preservation solution for 24 hours at 4°C. After transplantation of the left lung, the right recipient bronchus and pulmonary artery were clamped.Four of 6 animals each in the LPD and Celsior groups and all 6 a…

Pulmonary and Respiratory Medicinemedicine.medical_specialtyTime FactorsOxygenation indexSwinemedicine.medical_treatmentDisaccharidesElectrolytesGlutamatesmedicine.arterymedicineLung transplantationAnimalsHistidineMannitolTransplantationBronchusLungbusiness.industryCold IschemiaLiterOrgan PreservationGlutathioneSurgeryTransplantationPerfusionmedicine.anatomical_structureAnesthesiaPulmonary arterySurgeryFemaleCardiology and Cardiovascular MedicinebusinessPerfusionLung TransplantationThe Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation
researchProduct

The CB1Cannabinoid Receptor Drives Corticospinal Motor Neuron Differentiation through the Ctip2/Satb2 Transcriptional Regulation Axis

2012

The generation and specification of pyramidal neuron subpopulations during development relies on a complex network of transcription factors. The CB1cannabinoid receptor is the major molecular target of endocannabinoids and marijuana active compounds. This receptor has been shown to influence neural progenitor proliferation and axonal growth, but its involvement in neuronal differentiation and the functional impact in the adulthood caused by altering its signaling during brain development are not known. Here we show that the CB1receptor, by preventing Satb2 (special AT-rich binding protein 2)-mediated repression, increased Ctip2 (COUP-TF interacting protein 2) promoter activity, and Ctip2-po…

Pyramidal tractsCannabinoid receptorGeneral Neurosciencemedicine.medical_treatmentCellular differentiationBiologyMotor neuronEndocannabinoid systemArticleGlutamatergicmedicine.anatomical_structurenervous systemCorticospinal tractmedicinelipids (amino acids peptides and proteins)CannabinoidNeuroscienceThe Journal of Neuroscience
researchProduct

The Concise Guide To Pharmacology 2021/22: G Protein-Coupled Receptors

2021

The Concise Guide to PHARMACOLOGY 2021/22 is the fifth in this series of biennial publications. The Concise Guide provides concise overviews, mostly in tabular format, of the key properties of nearly 1900 human drug targets with an emphasis on selective pharmacology (where available), plus links to the open access knowledgebase source of drug targets and their ligands (www.guidetopharmacology.org), which provides more detailed views of target and ligand properties. Although the Concise Guide constitutes over 500 pages, the material presented is substantially reduced compared to information and links presented on the website. It provides a permanent, citable, point-in-time record that will s…

RMCytoplasmic and NuclearComputer scienceDatabases PharmaceuticalHumans; Ion Channels; Ligands; Receptors Cytoplasmic and Nuclear; Receptors G-Protein-Coupled; Databases Pharmaceutical; PharmacologyReceptors Cytoplasmic and NuclearIN-VITRO CHARACTERIZATIONPharmacologyLigandsIon ChannelsNORSlaw.inventionReceptors G-Protein-CoupledG-Protein-CoupledDatabases03 medical and health sciencesCALCIUM-SENSING RECEPTOR0302 clinical medicineDELTA-OPIOID RECEPTORlawSummary informationReceptorsHumansHISTAMINE H-3 RECEPTORFATTY-ACID RECEPTORMETABOTROPIC GLUTAMATE-RECEPTOR030304 developmental biologyG protein-coupled receptorPharmacologyGONADOTROPIN-RELEASING-HORMONE0303 health sciencesClinical pharmacologyFORMYL PEPTIDE RECEPTORMUSCARINIC ACETYLCHOLINE-RECEPTOR3. Good health317 Pharmacy030220 oncology & carcinogenesisPharmaceuticalNEGATIVE ALLOSTERIC MODULATORCatalytic receptors
researchProduct